TABLE 3.

Associations of Primary Short-Term and Long-Term Outcomes With Presence of Postnatal CMV Infection and Antiviral Treatment

				CMVPNT vs. NEG		CMVPT vs. NEG
	NEG (n = 50)	CMVPNT (n = 26)	CMVPT (n = 27)	OR (95% CI)	P	OR (95% CI)	P
Me (IQR) Length of stay [days]	94 (69–112)	85 (70–102)	100 (88–137)	0.99 (0.98–1.01)	0.457	1.01 (1–1.02)	0.103
Death before discharge [n (%)]	3 (6)	1 (3.8)	1 (3.7)	0.63 (0.06–6.34)	0.692	0.6 (0.06–6.09)	0.668
Hearing at follow-up
Normal hearing [n (%)]	30 (81.1)	13 (100)	17 (85)	–	0.032 a	1.32 (0.3–5.79)	0.711
Sensorineural hearing loss [n (%)]	7 (18.9)	0 (0)	3 (15)
Denver developmental screening test II
Me (IQR) Gross motor domain score	0.94 (0.8–1)	0.98 (0.88–1)	1 (0.96–1)	–	0.635b	–	0,115b
Me (IQR) Fine motor domain score	1 (0.92–1)	1.06 (0.98–1.23)	1 (0.88–1)	–	0.077b	–	0.694b
Me (IQR) Speech domain score	0.93 (0.83–1)	1 (0.9–1)	0.92 (0.88–1)	2.89 (0.11–72.82)	0.519	3.97 (0.2–79.6)	0.368
Me (IQR) Socialization domain score	1 (1–1)	1 (0.96–1)	1 (0.85–1)	0.77 (0.01–77.65)	0.91	1.26 (0.02–104.03)	0.918
Neurologic status
Normal [n (%)]	21 (56.8)	9 (69.2)	14 (70)	1.71 (0.45–6.58)	0.432	1.78 (0.56–5.65)	0.33
Abnormal [n (%)]	16 (43.2)	4 (30.8)	6 (30)

CI, confidence interval; CMV_PNT, CMV positive without antiviral treatment group; CMV_PT, CMV positive on antiviral therapy group; IQR, interquartile range; Me, median; n, number of subjects; NEG, CMV negative group (control group); OR, odds ratio.

^aOdds ratio test.

^bMann–Whitney U test.